Free Trial

Inhibikase Therapeutics (IKT) Institutional Ownership

→ The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad)
Free IKT Stock Alerts
$1.58
+0.21 (+15.33%)
(As of 05:27 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media

Institutional Ownership Changes (13F Filings) for Inhibikase Therapeutics (NYSE:IKT)

Current
Institutional Ownership
Percentage
3.81%
Number of
Institutional Buyers
(last 12 months)
2
Total
Institutional Inflows
(last 12 months)
$574.88K
Number of
Institutional Sellers
(last 12 months)
2
Total
Institutional Outflows
(last 12 months)
$1.93M
Get IKT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

IKT Institutional Buying and Selling by Quarter

Inhibikase Therapeutics Major Shareholders & Ownership History

Export to Excel
Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/15/2023Armistice Capital LLC186,046$259K0.0%-62.5%3.477%
9/21/2023Barclays PLC11,455$41K0.0%N/A0.214%
8/8/2023Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266%
5/2/2023Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286%
2/10/2023Blair William & Co. IL229,000$114K0.0%+27.9%0.817%
7/12/2022Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259%
5/6/2022Retirement Planning Co of New England Inc.116,402$172K0.1%-21.0%0.461%
5/5/2022Lynwood Capital Management Inc.120,000$178K0.2%-52.9%0.476%
5/4/2022Hamilton Lane Advisors LLC165,635$245K0.1%N/A0.657%
5/3/2022Redmond Asset Management LLC122,682$182K0.1%N/A0.486%
2/14/2022Murchinson Ltd.220,947$327K0.0%-31.2%0.878%
2/8/2022Retirement Planning Co of New England Inc.147,331$216K0.1%N/A0.586%
2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279%
11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019%
11/16/2021Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103%
11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202%
8/17/2021Zeke Capital Advisors LLC93,800$263K0.0%+398.9%0.926%
8/16/2021Antara Capital LP250,000$700K0.0%N/A2.467%
8/16/2021Warberg Asset Management LLC90,000$252K0.0%N/A0.888%
8/16/2021Sabby Management LLC421,200$1.18M0.2%N/A4.157%
8/13/2021Altium Capital Management LP109,749$307K0.1%N/A1.083%
8/13/2021Murchinson Ltd.320,947$899K0.3%N/A3.167%
8/13/2021Vanguard Group Inc.470,615$1.32M0.0%N/A4.644%
8/13/2021FMR LLC433,300$1.21M0.0%+333.3%4.276%
8/12/2021Kepos Capital LP700,000$1.96M0.1%N/A6.908%
5/21/2021Citadel Advisors LLC17,857$107K0.0%N/A0.178%
5/18/2021Millennium Management LLC11,224$67K0.0%N/A0.112%
5/18/2021Citadel Advisors LLC17,857$107K0.0%N/A0.178%
5/17/2021HRT Financial LP11,614$69K0.0%N/A0.115%
(Data available from 1/1/2016 forward)

IKT Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of IKT shares?

During the previous two years, the following institutional investors and hedge funds held shares of Inhibikase Therapeutics shares: Armistice Capital LLC ($259K), Redmond Asset Management LLC ($182K), Lynwood Capital Management Inc. ($178K), Retirement Planning Co of New England Inc. ($172K), Blair William & Co. IL ($114K), Hamilton Lane Advisors LLC ($50K), and Koshinski Asset Management Inc. ($49K).Learn more on IKT's institutional investors.

What percentage of Inhibikase Therapeutics stock is owned by institutional investors?

3.81% of Inhibikase Therapeutics stock is owned by institutional investors. Learn more on IKT's institutional investor holdings.

Which institutional investors have been buying Inhibikase Therapeutics stock?

The following institutional investors have purchased Inhibikase Therapeutics stock in the last 24 months: Hamilton Lane Advisors LLC ($248.45K), Redmond Asset Management LLC ($122.68K), Koshinski Asset Management Inc. ($65.38K), Blair William & Co. IL ($50K), and Barclays PLC ($11.46K).

How much institutional buying is happening at Inhibikase Therapeutics?

Institutional investors have bought a total of 497,966 shares in the last 24 months. This purchase volume represents approximately $3.58M in transactions.

Which Inhibikase Therapeutics major shareholders have been selling company stock?

The following institutional investors have sold Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($310.50K), Lynwood Capital Management Inc. ($135K), Hamilton Lane Advisors LLC ($69.02K), and Retirement Planning Co of New England Inc. ($30.93K).

How much institutional selling is happening at Inhibikase Therapeutics?

Institutional investors have sold a total of 545,445 shares in the last 24 months. This volume of shares sold represents approximately $3.40M in transactions.


Related Companies:
This page (NYSE:IKT) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners
SHOCKING Crypto Leak…
Crypto 101 Media
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
Traders Agency
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
Banyan Hill Publishing
Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!
American Alternative
How to camouflage a factory of 53,000 workers
Stansberry Research
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Exposed: 10 CENT Crypto to Explode April 20th?
True Market Insiders